FORMER FDA DEPUTY COMMISSIONER JOHN NORRIS TO TESTIFY BEFORE REP. DINGELL
FORMER FDA DEPUTY COMMISSIONER JOHN NORRIS TO TESTIFY BEFORE REP. DINGELL at a House Energy and Commerce/Oversight hearing scheduled for Oct. 15. Norris is scheduled to be the sole hearing witness as the subcommittee continues its probe into the generic drug approval process. Reportedly, Norris is being called before the subcommittee because of his reluctance to cooperate with the investigation. The subcommittee feels that Norris has delayed opportunities to be interviewed privately by the subcommittee staff. A subpoena has been issued to Norris to force him to testify publicly. Reportedly, the subcommittee is interested in questioning Norris about possible contacts he has had with companies having difficulties with FDA in his position as exec VP with the public relations firm Hill & Knowlton. The subcommittee has had to postpone additional hearings on the generic drug approval process and related compliance issues that were tentatively scheduled for November and December. Those hearings are expected to be rescheduled for sometime in the first quarter of 1990.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth